Estimation of Probability of Malignancy Using a Logistic Model Combining Physical Examination, Ultrasound, Serum CA 125, and Serum CA 72-4 in Postmenopausal Women with a Pelvic Mass: An International Multicenter Study

Schutter, Eltjo M.J.; Sohn, Christof; Kristen, P.; Möbus, V.; Crombach, G.; Kaufmann, M.; Caffier, H.; Kreienberg, R.; Verstraeten, A.A.; Kenemans, P.

doi:10.1006/gyno.1998.4942

Cited by 42 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The addition of serum CA-72-4 to the combination of pelvic examination, ultrasound and serum CA-125 led to an improved discrimination between malignant and benign pelvic masses [35].…”

Section: Multimarker Combinations Analyzed In Training Setsmentioning

confidence: 99%

Multiple Biomarker Panels For Early Detection of Ovarian Cancer

et al. 2006

View full text Add to dashboard Cite

Ovarian cancer is the eighth most common cause of cancer mortality in women. It is diagnosed in more than 20,000 women in the USA each year and approximately 15,000 women die of the disease annually. The majority of patients are diagnosed with advanced-stage ovarian cancer, as this deadly disease causes minimal and nonspecific symptoms until late in the course of the disease. No standardized screening test exists to reliably detect ovarian cancer. Cancer antigen (CA)-125 is a protein antigen found at abnormally high levels in the blood of many women with ovarian cancer. Most healthy women have CA-125 levels of below 35 units/microl of blood serum. However, a number of noncancerous conditions can cause elevated CA 125 levels, and many women with early-stage ovarian cancer have normal CA-125 levels. Owing to these limitations, this test is not recommended for routine screening in women who are not at high risk or who do not have specific symptoms of the disease. Currently, many researchers are focusing on simultaneous examination of multiple markers to increase sensitivity of the screening test for early detection of ovarian cancer. Analysis of the current literature shows that combining several biomarkers dramatically improves sensitivity of CA-125 in ovarian cancer patients. This article provides a comprehensive overview of existing studies in the area of multimarker panel development for the early detection and monitoring of ovarian cancer. Our literature review demonstrates that a multimarker approach for the generation of a prototype assay for early detection of ovarian cancer has a great potential to lead to the development of a screening test for this disease.

show abstract

“…The addition of serum CA-72-4 to the combination of pelvic examination, ultrasound and serum CA-125 led to an improved discrimination between malignant and benign pelvic masses [35].…”

Section: Multimarker Combinations Analyzed In Training Setsmentioning

confidence: 99%

Multiple Biomarker Panels For Early Detection of Ovarian Cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Some authors have developed prediction models that combine patient characteristics, sonographic results, and serum markers [2][3][4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis

Geomini¹,

Bremer²,

Kruitwagen³

et al. 2005

Gynecologic Oncology

View full text Add to dashboard Cite

“…However, the combination of TVU, CA125, and CA72-4 increased the reliability of identifying a pelvic mass as benign or malignancy to 87%. 44 Thus, CA72-4 may be a promising tumor marker to be used in conjunction with CA125.…”

Section: Ca72-4mentioning

confidence: 99%